Salicin

Chemical Class	Phenolic glycoside (salicyl alcohol glucoside)
Molecular Formula / CAS	C₁₃H₁₈O₄ · CAS 138-52-3
Primary Botanical Source(s)	White willow bark (Salix alba)
Plant Part	Bark
Typical Content	The principal marker compound of standardised willow bark extract, typically standardised to 15–25%
Solubility / Format	Water-soluble glycoside; available as high-purity isolate and standardised bark extract powders
Sourcing Status	Product-live — genuine match via Herbuno’s white willow bark extract line
Buy from Herbuno	Salicin 98% Powder (High-Purity Isolate) · Salicin 25% Powder (Standardized Extract)

Name origin: Salicin takes its name from Salix, the willow genus from which it was first isolated in 1828 by French pharmacist Henri Leroux, and it is in turn the etymological root of the word “salicylic” and, by extension, aspirin’s active compound family. Traditional use: Willow bark has one of the longest continuously documented pain-relief histories in the historical record, referenced in Egyptian, Sumerian and Greek medical texts including Hippocrates’ recommendation of willow leaf tea for pain and fever, with this traditional reputation persisting essentially unbroken through European folk medicine into the modern herbal supplement era. Research trajectory: Salicin’s isolation in the 1820s directly enabled the chemical work that led to salicylic acid synthesis and, eventually, Bayer’s 1897 development of acetylsalicylic acid (aspirin), making willow bark one of the clearest historical bridges between traditional herbal medicine and modern pharmaceutical chemistry; modern clinical research has returned to willow bark extract itself, running direct randomised trials against pain conditions and, in some studies, against pharmaceutical comparators. Commercial source: White willow bark is the standard commercial source of salicin, and Herbuno’s standardised extracts reflect this well-established, genuine botanical match.

---

Evidence for Salicin Applications

Salicin itself is largely inactive until metabolised: after ingestion, gut bacteria and liver enzymes convert salicin to salicyl alcohol and then to salicylic acid, the same active metabolite produced by aspirin metabolism, though via a different and notably slower conversion pathway that appears to spare much of the direct gastric-mucosa irritation associated with synthetic aspirin. A review of white willow bark extract research describes this anti-inflammatory activity as linked to downregulation of TNF-alpha and NF-κB inflammatory mediators, alongside salicin’s conversion to salicylic acid (Shara & Stohs 2015). Claim strength: Moderate.

A randomised, double-blind trial in 210 patients with acute exacerbations of chronic low back pain found that willow bark extract standardised to 240 mg salicin per day produced significantly more pain-free patients (39%) than a 120 mg low-dose group (21%) or placebo (6%) by the final week of treatment, using tramadol as the sole permitted rescue medication (Chrubasik et al. 2000). This is one of the more robust human trials in the willow bark literature, with a clear dose-response relationship and a substantial patient cohort. Claim strength: Moderate.

A 2023 meta-analysis of randomised controlled trials evaluating willow bark for arthritis pain relief synthesised the accumulated clinical trial evidence across osteoarthritis and rheumatoid arthritis populations, following PRISMA guidelines and formal risk-of-bias assessment (et al. 2023). Separate individual trials within this literature have found willow bark extract (240 mg salicin/day) comparable to low-dose diclofenac in some outcome measures, though generally with a more modest effect size than full-dose conventional NSAIDs. Claim strength: Moderate.

Because salicin converts to a salicylate metabolite, formulators and consumers with aspirin or NSAID sensitivity, including salicylate allergy, should treat willow bark extract with the same caution applied to aspirin-family compounds, despite willow bark’s reputation as a gentler “natural” alternative. This caution is grounded in shared pharmacology, not merely a generic herbal-supplement disclaimer. Claim strength: Moderate.

The clinical trials underpinning willow bark’s pain-relief reputation consistently use extract standardised to a specific salicin content (most commonly 240 mg/day), not raw willow bark material of unspecified potency; formulators should treat salicin percentage as the operative dosing specification for any pain-relief-oriented positioning, since unstandardised willow bark preparations can vary substantially in actual salicin delivery. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical trials supporting willow bark’s pain-relief evidence base most consistently use extract standardised to 120–240 mg salicin per day, with the higher dose showing stronger effects in head-to-head low back pain and osteoarthritis trials; effects typically become apparent within one to two weeks of regular use rather than as an immediate single-dose analgesic.

Analytical quantification of salicin content is performed by HPLC, the standard method used across the clinical trial literature and pharmacopoeial monographs for willow bark; formulators should request HPLC-verified salicin percentage rather than a generic tannin or total-phenolic figure, since salicin content does not correlate reliably with total phenolic content across willow bark lots.

Because salicin metabolises to a salicylate compound, formulation and labelling should account for the same interaction considerations applied to aspirin and other salicylates, including caution around concurrent anticoagulant use and salicylate sensitivity; this is a genuine pharmacological consideration rather than a boilerplate herbal caution.

Regulatory positioning for salicin-standardised willow bark extract follows established botanical pain-relief supplement precedent in most markets, with willow bark carrying Commission E and similar traditional-use monograph recognition in several European regulatory frameworks. Formulators should verify local labelling requirements around salicylate-related cautions in their target markets.

---

Frequently Asked Questions — Salicin

Related compounds: Gallic Acid, Rosmarinic Acid